Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 30;3(4):161-173.
doi: 10.1016/j.ncrna.2018.08.001. eCollection 2018 Dec.

Relations between approved platinum drugs and non-coding RNAs in mesothelioma

Bernhard Biersack  1
Affiliations
Review

Relations between approved platinum drugs and non-coding RNAs in mesothelioma

Bernhard Biersack. Noncoding RNA Res. .

Erratum in

Abstract

Malignant mesothelioma diseases feature an increasing risk due to their severe forms and their association with asbestos exposure. Platinum(II) complexes such as cisplatin and carboplatin are clinically approved for the therapy of mesothelioma often in combination with antimetabolites such as pemetrexed or gemcitabine. It was observed that pathogenic properties of mesothelioma cells and the response of mesothelioma tumors towards platinum-based drugs are strongly influenced by non-coding RNAs, in particular, by small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). These non-coding RNAs controlled drug sensitivity and the development of tumor resistance towards platinum drugs. An overview of the interactions between platinum drugs and non-coding RNAs is given and the influence of non-coding RNAs on platinum drug efficacy in mesothelioma is discussed. Suitable non-coding RNA-modulating agents with potentially beneficial effects on cisplatin treatment of mesothelioma diseases are mentioned. The understanding of mesothelioma diseases concerning the interactions of non-coding RNAs and platinum drugs will optimize existing therapy schemes and pave the way to new treatment options in future.

Keywords: ABC, ATP-binding cassette; AKBA, 3-acetyl-11-keto-β-boswellic acid; AKI, acute kidney injury; Anticancer drugs; Bcl-2, B-cell lymphoma 2; CAF, cancer-associated fibroblast; CBDCA, cyclobutane-1,1-dicarboxylate; Carboplatin; Cisplatin; DADS, diallyl sulfide; DHA, docosahexaenoic acid; DIM, 3,3′-diindolylmethane; DMPM, diffuse malignant peritoneal mesothelioma; EGCG, epigallocatechin-3-gallate; EMT, epithelial-mesenchymal transition; HOTAIR, HOX transcript antisense RNA; I3C, indole-3-carbinol; Long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MPM, malignant pleural mesothelioma; MRP1, multidrug resistance protein 1; Mesothelioma; MicroRNA; NSCLC, non-small cell lung cancer; NaB, sodium butyrate; PDCD4, programmed cell death 4; PEG, polyethylene glycole; PEITC, phenethylisothiocyanate; PTEN, phosphatase and tensin homolog; RA, retinoic acid; SAHA, suberoylanilide hydroxamic acid; SFN, sulforaphane; TNBC, triple-negative breast cancer; TSA, trichostatin A.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structures of the clinically approved platinum(II) complexes cisplatin and carboplatin.
Fig. 2
Fig. 2
Cisplatin and non-coding RNAs in mesothelioma.
Fig. 3
Fig. 3
Non-coding RNA modulating agents with relevance to cisplatin activity.
Fig. 4
Fig. 4
Possible activity boost of approved anticancer drugs by cisplatin-mediated miRNA modulation.
Fig. 5
Fig. 5
Activation of p53 and miR-34a induction by platinum complexes.
See this image and copyright information in PMC

References

    1. Odgerel C.-O., Takahashi K., Sorahan T., Driscoll T., Fitzmaurice C., Yoko-o M., Sawanyawisuth K., Furuya S., Tanaka F., Horie S., van Zandwijk N., Takala J. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup. Environ. Med. 2017;74:851–858. - PMC - PubMed
    1. Sterman D.H., Albelda S.M. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology. 2005;10:266–283. - PubMed
    1. Husain A.N., Colby T.V., Ordonez N.G., Allen T.C., Attanoos R.L., Beasley M.B., Butnor K.J., Chirieac L.R., Churg A.M., Dacic S., Galateau-Sallé F., Gibbs A., Gown A.M., Krausz T., Litzky L.A., Marchevsky A., Nicholson A.G., Roggli V.L., Sharma A.K., Travis W.D., Walts A.E., Wick M.R. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab Med. 2018;142:89–108. - PubMed
    1. Brims F.J., Meniawy T.M., Duffus I., de Fonseka D., Segal A., Creaney J., Maskell N., Lake R.A., de Klerk N., Nowak A.K. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis. J. Thorac. Oncol. 2016;11:573–582. - PubMed
    1. Collins D.C., Constantinidou A., Sundar R., Chenard-Poirier M., Yap T.A., Banerji U., de Bono J.S., Lopez J.S., Tunariu N. Patterns of metastases in malignant pleural mesothelioma in the modern era: redefining the spread of an old disease. J. Clin. Oncol. 2017;35 8556-8556.